A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

Eirini Panoilia,Emilie Schindler,E. Samantas,Gerasimos Aravantinos,Haralabos P. Kalofonos,Christos Christodoulou,George P. Patrinos,Lena E. Friberg,Gregory Sivolapenko

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

2015

Eirini Panoilia
Emilie Schindler
E. Samantas
Gerasimos Aravantinos
Haralabos P. Kalofonos
Christos Christodoulou
George P. Patrinos
Lena E. Friberg
Gregory Sivolapenko

Purpose To characterize the population pharmacokinetics of bevacizumab, its binding properties to VEGF165 and the effect of demographic data and VEGF-A polymorphisms on the interplay between bevacizumab serum pharmacokinetics and VEGF165 serum concentrations in patients with colorectal cancer stage IV.

Keywords:

Bevacizumab
Pharmaceutical sciences
Vascular endothelial growth factor A
Colorectal cancer
Population
Pharmacology
Oncology
VEGF receptors
Internal medicine
Medicine
Pharmacokinetics
binding properties
demographic data
serum concentration
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations